Santen Pharmaceutical Co., Ltd.
4536.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.32 | -0.07 | 0.19 | 0.09 |
| FCF Yield | 10.98% | 11.89% | 2.87% | 2.08% |
| EV / EBITDA | 6.33 | 8.18 | 29.10 | 8.08 |
| Quality | ||||
| ROIC | 13.04% | 13.42% | 24.71% | 7.25% |
| Gross Margin | 57.01% | 59.18% | 59.52% | 58.81% |
| Cash Conversion Ratio | 1.68 | 2.73 | -2.48 | 1.69 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.44% | 4.28% | 3.79% | 3.30% |
| Free Cash Flow Growth | -12.42% | 393.37% | 23.10% | -32.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.85 | -1.05 | -1.52 | -0.92 |
| Interest Coverage | 20.70 | 19.48 | 21.36 | 29.68 |
| Efficiency | ||||
| Inventory Turnover | 2.50 | 2.85 | 2.87 | 2.95 |
| Cash Conversion Cycle | 123.36 | 166.13 | 185.65 | 178.86 |